Evaluation of ferroptosis inhibition for the treatment of ischemia/reperfusion injury upon liver transplantation: A first-in-man pilot study
Liver transplantation is the standard treatment for end-stage liver failure. However, due to a lack of sufficient donor organs, the use of livers from “extended criteria donors”, so-called marginal (inferior) organs, is increasing, ultimately leading to a dramatically higher incidence of transplantation-induced ischemia-reperfusion injury (IRI).
During the course of this project, a first-in-man study will be conducted that will pave the way for the development of an innovative anti-IRI treatment. The approach is based on the early inhibition of a specific form of cell death, known as ferroptosis. To combat these tissue-deteriorating processes, newly developed ferroptosis inhibitors will be administered to livers during the pre-operative preparation phase prior to implantation. This is intended to minimize direct, IRI-related tissue damage and an associated detrimental immune cell activation.
The results of this study will, for the first time, address the therapeutic benefits of ferroptosis inhibitors in solid organ transplantation.
Additional Information can be found at:
https://www.helmholtz-muenchen.de/mcd/index.html
http://www.conradlaboratory.com
Project partners:
Dr. Bettina Proneth
Helmholtz Zentrum München
Institut für Metabolismus und Zelltod
Ingolstädter Landstr. 1
85764 Neuherberg
Prof. Edward Geissler
PD Dr. Elke Eggenhofer
Klinik und Poliklinik für Chirurgie
Universitätsklinikum Regensburg
Franz-Josef-Strauss Allee 11
93053 Regensburg